Important Updates On Paxlovid During Omicron – Age, Vaccination Status, And Natural Immunity

Share

Whiteboard Doctor

New data on Paxlovid. Things you should know!

Paxlovid, or Nirmatrelvir-Ritonavir, has become the treatment of choice for outpatient COVID-19 in higher risk individuals.

New data has come out though to help guide this, specifically during the Omicron surge in those young and old, vaccinated, and unvaccinated, and previously infected.


https://www.nejm.org/doi/full/10.1056… The original study done on Paxlovid was done in those unvaccinated during the Delta surge. It showed an almost 90% decrease risk in progressing to severe COVID-19 in this population. What about during Omicron and in those vaccinated or previously infected?

https://www.medscape.com/viewarticle/… We have started to see some signs of “rebound” COVID-19 after treatment with Paxlovid. This is where the symptoms resolve and you often test negative, just to then redevelop symptoms and test positive again within a week of symptom resolution.

The CDC put out a warning on this last week that we covered here: https://www.youtube.com/watch?v=60Rro….

https://assets.researchsquare.com/fil… New preprint study published that found a decreased risk of hospitalization in those greater than 65 years old, even if they were previously infected and/or vaccinated.